The Delhi high court on Wednesday observed that an investigation initiated by the Competition Commission of India (CCI) against Roche Products (India) for abuse of dominant position was an ‘interference in the administration of justice’.
CCI had initiated investigation against Roche and held it to be abusing its position as a market leader resulting in denial of market access to other pharmaceutical companies.
The regulator’s order was based on written communications by Roche to authorities including the Director Controller General of India (DCGI), National Pharmaceutical Pricing Authority (NPPA) and hospitals/potential buyers discouraging them from buying biosimilar versions of its cancer drug, Trastuzumab sold by its competitors— Mylan and Biocon.
Full Content: Outlook India
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
